预约演示

Novo Nordisk inks $1B Cardior buyout to pump up heart failure plans

2024-03-25

交易

临床2期寡核苷酸临床3期细胞疗法

Novo Nordisk moved to buy Cardior Pharmaceuticals after identifying CDR132L as a molecule with “a distinctive mode of action.”

Novo Nordisk is pumping upCardior Pharmaceuticalss. The drugmaker, sCDR132Lby its GLP-1 windfall, has decided to buy Cardior Pharmaceuticals and its midphase prospect in a deal that could top out above 1 billion euros ($1.1 billion).

Novo Nordiskeveloping an antiseheart failureeotide to inhibit a piece of non-coding RNA, miR-132, that is implicated Cardior Pharmaceuticalsulation of the RNA when certain cells are stressed can lead to changes in the size and shape of the heart. Blocking elevated miR-132 could therefore prevent or reverse changes that are associated with poor prognosis in patients who have heart attacks.

Cardiortech raised 64 million euros from investors including Bristol Myers Squibb in 2021miR-132ed the cash to take (PDFheart failurecleotide, CDR132L, into a phase 2 trial the next year. Cardior has designed the 280-subject study to show CDR132L’s effect on the vomiR-132 blood in part of the heart.heart attacks

Cardior is still months away from the primary completion of tBristol Myers Squibbto ClinicalTrials.gov, but Novo Nordisk is already planning toCDR132L development. The Danish drugmaker plaCardiorun another phase 2 trial in chronic heart faCDR132Latients with cardiac hypertrophy, a condition that negatively affects the heart’s ability to pump blood.

Cardior will slot into a pipeline that already features heart failure programs. Novo Nordisk reported clinicNovo Nordiska on semaglutide, the active ingredient in Ozempic and Wegovy, in heart failure patients last year. Thechronic heart failure phase 3 trial cardiac hypertrophyor ziltivekimab in a heart failure patient population and is working with Heartseed to test a cell therapy in an early-phase study.

Novo Nordisk moved to buy Cardior after identifying CDR1heart failurecule with “Novo Nordiske mode of action” that has the “psemaglutide become a first-in-class thOzempicesignWegovyhalt heart failurereverse the course of disease for people living with heart failure.IL-6 inhibitor IL-6vances in tziltivekimab of heheart failureave so far largely focused on managing tHeartseedms. CDR132L could address the underlying causes.

Novo Nordiskl for CDR132L Cardioride long-lasting imCDR132Lnt in heart function led Novo Nordisk to put together an offer worth up to 1.025 billion euros for Cardior. The package includes an upfront payment and milestones, but neither party has provideheart failure of the deal.heart failure CDR132L

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构